Lundbeck to test Vyepti in direct comparison with competitors
In a new phase IV real-world study, Lundbeck will test how well migraine infusion Vyepti does compared to other therapies of the same class.
by MIKKEL AABENHUS HEMMINGSEN & CHRISTIAN BUNDGAARD, translated by daniel pedersen
200 people in the US will help shed light on how well the newest generation of migraine therapies perform in a direct comparison of their preventive effects on migraine episodes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer to acquire migraine firm for over USD 11bn
For subscribers
.jpg)
.jpg&w=384&q=75)
